Treatment duration (persistence) of basal insulin supported oral therapy (BOT) in Type-2 diabetic patients: comparison of insulin glargine with NPH insulin

Quinzler, Renate; Ude, Miriam; Franzmann, Alexandra; Feldt, Sandra; Schüssel, Katrin; Leuner, Kristina; Müller, Wernér E.G.; Dippel, FW; Schulz, Martin

doi:10.5414/cp201572

Cited by 10 publications

(9 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The high baseline values are consistent with large initial HbA1c reductions even for non-insulin therapies [20][21][22]. These large initial falls in HbA1c have been reported in other observational studies, and attributed as much to educational/behavioural change as to the insulin itself [4], though in clinical database studies, poorer glucose is reported [8], and is perhaps associated with greater persistence of initial therapy [8,23,24]. The average levels achieved were not to internationally endorsed levels: <7.0% (<53 mmol/mol), but the population studied had a long duration of diabetes, with significant comorbidities.…”

Section: Discussionsupporting

confidence: 55%

Four-year evolution of insulin regimens, glycaemic control, hypoglycaemia and body weight after starting insulin therapy in type 2 diabetes across three continents

Home¹,

Dain²,

Freemantle³

et al. 2015

Diabetes Research and Clinical Practice

View full text Add to dashboard Cite

show abstract

Section: Discussionsupporting

confidence: 55%

Four-year evolution of insulin regimens, glycaemic control, hypoglycaemia and body weight after starting insulin therapy in type 2 diabetes across three continents

Home¹,

Dain²,

Freemantle³

et al. 2015

Diabetes Research and Clinical Practice

View full text Add to dashboard Cite

show abstract

“…2,10 Persistence with basal insulin therapy, defined as the time period between the initiation and the end of therapy, was also higher for glargine than for other basal insulins. 11,12 Patients on detemir had a higher risk of switching from BOT to ICT than glargine users. 11 Furthermore, the risk of switching to ICT was also significantly higher for patients on NPH insulin (BOT) compared with glargine users.…”

mentioning

confidence: 99%

Different Injection Frequencies of Basal Insulins in Type 2 Diabetes Patients under Real-Life Conditions: A Retrospective Database Analysis

Rathmann

Dippel

Kostev³

2013

J Diabetes Sci Technol

View full text Add to dashboard Cite

Abbreviations: (BMI) body mass index, (BOT) basal-supported oral therapy, (HbA1c) glycosylated hemoglobin, (ICT) intensified conventional therapy, (NPH) Abstract Aims:Little is known about routine use of basal insulins [glargine, detemir, neutral protamine Hagedorn (NPH)] in primary care patients with type 2 diabetes. The aim was to compare injection frequencies of basal insulins in type 2 diabetes in primary care practices, both for basal-supported oral therapy (BOT) and basal-bolus treatment [intensified conventional therapy (ICT)] regimens. Methods:Primary care data from 4211 glargine (BOT/ICT, 2247/1964), 1290 detemir (490/800), and 3876 NPH (1331/2425) insulin users were retrospectively analyzed (Disease Analyzer database, May 2009-April 2012). Logistic regression (>1 daily injection) and propensity scores were used to adjust for various confounders (age, sex, type of physician, dosage, body mass index, glycosylated hemoglobin). Results:Overall, >1 daily injections were observed in 7.5% of glargine users (BOT, 6.2%; ICT, 9.0%), which was lower than for detemir (overall, 25.4%; BOT, 22.0%; ICT, 27.4%) and NPH (25.4%; BOT, 23.9%; ICT, 27.2%) insulin (all p < .001). The adjusted odds of having >1 injection was lower for glargine compared with detemir (odds ratio, 0.26; 95% CI 0.22-0.32) and ). Similar results were found for BOT or ICT and after propensity score matching. Conclusions:Glargine is associated with significantly lower injection frequencies than other basal insulins. These findings might impact patient-reported outcomes, quality of life, treatment satisfaction, and economic aspects of diabetes treatment.

show abstract

“…Patients initiating insulin glargine were more persistent compared with detemir (80% vs. 68%, p < 0.0001) during ≥12 months follow-up [14]. A retrospective cohort study from an analysis of claims data from prescriptions for ambulatory patients within the German Statutory Health Insurance scheme also showed that type 2 diabetes patients under BOT with insulin glargine stayed significantly longer on the initial therapy before switching to ICT than patients on BOT using NPH insulin [15]. A Markov model was developed simulating the transition from BOT to ICT during a treatment course of 10 years based on German data (Disease Analyzer, Statutory Health Insurance) [16].…”

Section: Discussionmentioning

confidence: 88%

Treatment persistence after initiating basal insulin in type 2 diabetes patients: A primary care database analysis

Pscherer¹,

Chou

Dippel

et al. 2015

Primary Care Diabetes

Self Cite

View full text Add to dashboard Cite

Treatment duration (persistence) of basal insulin supported oral therapy (BOT) in Type-2 diabetic patients: comparison of insulin glargine with NPH insulin

Cited by 10 publications

References 13 publications

Four-year evolution of insulin regimens, glycaemic control, hypoglycaemia and body weight after starting insulin therapy in type 2 diabetes across three continents

Four-year evolution of insulin regimens, glycaemic control, hypoglycaemia and body weight after starting insulin therapy in type 2 diabetes across three continents

Different Injection Frequencies of Basal Insulins in Type 2 Diabetes Patients under Real-Life Conditions: A Retrospective Database Analysis

Treatment persistence after initiating basal insulin in type 2 diabetes patients: A primary care database analysis

Contact Info

Product

Resources

About